GAMBACORTI PASSERINI CARLO

Posizione organizzativa:
Ruolo:
Professore ordinario
Settore scientifico disciplinare:
Malattie del sangue (MEDS-09/B)
Gruppo scientifico disciplinare:
MALATTIE DEL SANGUE, ONCOLOGIA E REUMATOLOGIA (06/MEDS-09)
Stanza:
  • U08, Piano: 4, Stanza: 4-12
  • U08, Piano: 4, Stanza: 4041

Pubblicazioni

  • Manghisi, B., Cotilli, G., Fedele, M., Perfetti, P., Terruzzi, E., Verga, L., et al. (2025). Case Report: Successful use of emapalumab in adult B-cell acute lymphoblastic leukemia experiencing severe neurotoxicity and hemophagocytic lymphohistiocytosis-like features after CAR-T cell therapy. FRONTIERS IN IMMUNOLOGY, 16 [10.3389/fimmu.2025.1563736]. Dettaglio

  • Kogan, M., Alviano, A., Catalano, M., Casiraghi, A., Ghilardi, G., Rindone, G., et al. (2025). Remission of low-grade lymphomatoid granulomatosis with extensive pulmonary involvement following immune restoration via antiretroviral therapy in a newly diagnosed HIV patient. AIDS RESEARCH AND THERAPY, 22(1) [10.1186/s12981-025-00717-9]. Dettaglio

  • Civettini, I., Zappaterra, A., Corti, P., Messina, A., Aroldi, A., Biondi, A., et al. (2025). Hb Monza: A novel extensive HBB duplication with preserved α-β subunit interaction and unstable hemoglobin phenotype. MED, 6(4) [10.1016/j.medj.2024.11.007]. Dettaglio

  • Frustaci, A., Zappaterra, A., Turri, G., Rossi, V., Deodato, M., Gambacorti‐passerini, C., et al. (2025). Pirtobrutinib is an Effective Salvage Treatment After Ibrutinib in Bing–Neel Syndrome. AMERICAN JOURNAL OF HEMATOLOGY, 100(10), 1878-1881 [10.1002/ajh.27759]. Dettaglio

  • Fontana, D., Malighetti, F., Villa, M., Zambon, A., Gambacorti-Passerini, C., Mologni, L. (2024). Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1. Intervento presentato a: Under 40 in Hematology. Giovani ematologi a confronto, Milano, Italia. Dettaglio

Progetti di ricerca

Bioinformatic integration of clonal hierarchies, mutational and functional landscapes of tumors to build a theragnostic tool in cancer treatment
Anno: 2021
Bando: FAQC 2021 - terza finestra
Enti finanziatori: Università degli Studi di MILANO-BICOCCA
FANTOM - Future of ALCL: Novel Therapies, Origins, Bio-Markers and Mechanism of resistance
Anno: 2021
Bando: MSCA Doctoral Networks 2021
Enti finanziatori: EUROPEAN COMMISSION
Molecular pathogenesis of atypical CML: Converting NGS-obtained data into therapeutically relevant information - V annualità
Anno: 2021
Bando: 2017-005 - Call for Proposals 2017 Investigator Grant (IG)
Enti finanziatori: FONDAZIONE AIRC
Molecular pathogenesis of atypical CML: Converting NGS-obtained data into therapeutically relevant information - IV annualità
Anno: 2020
Bando: 2017-005 - Call for Proposals 2017 Investigator Grant (IG)
Enti finanziatori: FONDAZIONE AIRC
HARMONY PLUS-Clonal hierarchy in CML
Anno: 2019
Bando: Restricted Call to maximise impact of IMI2 JU objectives and scientific priorities
Enti finanziatori: EUROPEAN COMMISSION

Premi e responsabilità scientifiche

Premi

  • ABILITAZIONE SCIENTIFICA NAZIONALE A PROFESSORE DI I FASCIA, SSD MED015, MIUR, 2013

Incarichi di insegnamento o ricerca

  • Professore a contratto - Professor of Oncology and hematology, Canada research Chair, Dept of Oncology, Jewish General Hospital, Montreal, Canadà - McGill University, 2003 - 2008

Congressi/Convegni

  • Program chair - 5th ERIA meeting, "20 year of anniversary of the discovery of ALK", 2014